Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics Q1 revenue rises to $204.9 million and raises 2026 revenue guidance

Positive Impact 4 of 5 earnings Written later

TG Therapeutics reported first quarter 2026 total revenue of $204.9 million, up from $120.9 million a year earlier, and net income of $19.8 million, up from $5.1 million. The company raised its full-year 2026 total global revenue target to approximately $925 million and its BRIUMVI U.S. net product revenue target to $885-900 million, from $825-850 million.

Key points

  • Total revenue was $204.9 million versus $120.9 million for Q1 2025; BRIUMVI U.S. net product revenue was $194.8 million, about 63% higher year over year.
  • Net income was $19.8 million, with diluted EPS of $0.12 versus $0.03 in Q1 2025.
  • SG&A expense rose to $88.2 million from $50.3 million, and R&D expense was $48.4 million versus $46.4 million.
  • Second quarter 2026 BRIUMVI U.S. net product revenue target is approximately $220 million.

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECMay 6, 2026, 7:25 AM ET
Accession number0001437749-26-015013

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.